Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …

Oncolytic viruses (OVs) have attracted growing awareness in the twenty-first century, as they
are generally considered to have direct oncolysis and cancer immune effects. With the …

Despite advances in neurosurgery, chemotherapy and radiotherapy, glioblastoma remains
one of the most treatment-resistant CNS malignancies, and the tumour inevitably recurs. The …

Here, we report the results of a phase I/II, single-arm study (UMIN-CTR Clinical Trial Registry
UMIN000002661) assessing the safety (primary endpoint) of G47∆, a triple-mutated …

Immunotherapy failures can result from the highly suppressive tumour microenvironment
that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM),. Here …

Oncolytic virus (OV) therapy is now something of a misnomer. The initial paradigm was that
naturally occurring or genetically engineered viruses would preferentially infect, replicate in …

Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …

Glioblastoma is the most common and aggressive primary malignant brain tumour. The
prognosis of patients with glioblastoma is poor, and their overall survival averages at 1 year …

Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …

Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The
standard of care offers minimal clinical benefit, and most GBM patients experience tumor …